|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Abbott |
| Information provided by: | Abbott |
| ClinicalTrials.gov Identifier: | NCT00292396 |
Purpose
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis
| Condition | Intervention | Phase |
|
Psoriasis |
Drug: Anti IL-12 monoclonal antibody/ABT-874/up to 12 weeks |
Phase II |
| MedlinePlus related topics: | Psoriasis |
| ChemIDplus related topics: | Interleukin-12 |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | M05-736 |
| First Received: | February 14, 2006 |
| Last Updated: | August 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00292396 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|